Accretive Health upgraded at Goldman
AH was upgraded from Neutral to Buy, Goldman Sachs said. $31 price target. Stock is attractive, following a 38% selloff.
-----
Acme Packet numbers reduced at Goldman
Shares of APKT now seen reaching $35, according to Goldman Sachs. Estimates also cut, given slower expected revenue growth. Neutral rating.
-----
Alaska Air numbers raised at Citigroup
Shares of ALK now seen reaching $81, according to Citigroup. Estimates also increased leading fundamentals and attractive valuation. Buy rating.
-----
Alaska Air estimates raised at UBS
ALK estimates increased through 2012, UBS said. Solid 3Q and 2012 cost guidance positive. Maintain $81 price target and Buy rating.
-----
Alexion Pharmaceuticals numbers upped at Jefferies
ALXN estimates were boosted through 2012, Jefferies said. Company is seeing higher Soliris sales and cutting costs. Hold rating and new $58 price target.
-----
Alexion Pharmaceutical estimates, target raised at UBS
Shares of ALXN now seen reaching $70, according to UBS. Estimates also increased on aHUS and margins. Neutral rating.
-----
Altera estimates, target reduced at Jefferies
ALTR estimates were cut through 2012, Jefferies said. Inventories are falling. Buy rating and new $43 price target.
-----
Altera estimates, target cut at UBS
Shares of ALTR now seen reaching $44.50, according to UBS. Estimates also lowered as weak macro slows secular growth. Buy rating.
-----
Associated Banc-Corp numbers lowered at Jefferies
Shares of ASBC now seen reaching $11, according to Jefferies. Estimates also cut, given reduced net interest income expectations. Buy rating.
-----
AT&T estimates lowered at Citigroup
T estimates lowered through 2012, Citigroup said. Reflects an elevation in dilution from a rapid adoption of Smartphones. Maintain $32 price target and Buy rating.
-----
Autonation estimates, target raised at Goldman
Shares of AN now seen reaching $34, according to Goldman Sachs. Estimates also increased, given better realized operating margin. Sell rating.
-----
AutoNation estimates lowered at UBS
AN estimates lowered through 2011, UBS said. Margins tailwinds end post Q3. Maintain $30 price target and Sell rating.
-----
Baxter estimates, target reduced at Goldman
BAX estimates were cut through 2014, Goldman Sachs said. Lower sales are hurting margins. Buy rating and new $66 price target.
-----
Blackstone estimates adjusted at Citigroup
BX estimates were adjusted through 2012, Citigroup said. Reflects the 3Q shortfall, but also stronger long term asset gathering outlook. Maintain $18 price target and Buy rating.
-----
Capital One numbers increased at Goldman
COF estimates were raised through 2013, Goldman Sachs said. Higher revenue is driving margin expansion. Neutral rating and new $51 price target.
-----
Chipotle Mexican Grill estimates lowered at UBS
CMG estimates lowered through 2012, UBS said. Sales beat, margins miss, view unchanged. Maintain $345 price target and Neutral rating.
-----
Chubb estimates lowered at UBS
CB estimates lowered through 2012, UBS said. Guidance revised downward based on heavy 3Q cat losses. Maintain $70 price target and Buy rating.
-----
Cooper Industries numbers boosted at Goldman
Shares of CBE now seen reaching $55, according to Goldman Sachs. Estimates also upped, given better margin visibility. Neutral rating.
-----
Covance estimates, target reduced at Jefferies
CVD estimates were cut through 2012, Jefferies said. Company still has excess capacity. Hold rating and new $53 price target.
-----
Covanta upgraded at Ardour
CVA was upgraded from Accumulate to Buy, Ardour Capital said. $21 price target. Company has a strong earnings base and the stock is attractive, following a recent pullback.
-----
Danaher estimates, target upped at Goldman
DHR estimates were boosted through 2013, Goldman Sachs said. Company is realizing higher margins and paying lower interest expense.
-----
Eldorado Gold upgraded at Canaccord
EGO was upgraded from Hold to Buy, Canaccord said. $21.50 price target. Enhanced production profile and dividend policy leads to bump in valuation.
-----
Eli Lilly estimates cut at Credit Suisse
LLY estimates were reduced through 2013, Credit Suisse said. Company will likely not cut costs as quickly as expected. Neutral rating and $39 price target.
-----
Flextronics estimates, target raised at Citigroup
Shares of FLEX now seen reaching $7, according to Citigroup. Estimates also increased on a more optimistic margin outlook. Neutral rating.
-----
Flextronics estimates, target boosted at Goldman
Shares of FLEX now seen reaching $5.25, according to Goldman Sachs. Estimates also upped, given higher sales and lower interest expense. Sell rating.
-----
Freescale estimates, target cut at Credit Suisse
FSL estimates were reduced through 2012, Credit Suisse said. Cellular business remains weak. Outperform rating and new $18 price target.
-----
Hershey estimates, target boosted at Credit Suisse
Shares of HSY now seen reaching $70, according to Credit Suisse. Estimates also upped, as the company has solid pricing power. Outperform rating.
-----
Huntington Bancshares numbers cut at Jefferies
HBAN estimates were reduced through 2012, Jefferies said. Company's costs remain high. Buy rating and new $6 price target.
-----
Huntington Bancshares downgraded at Oppenheimer
HBAN was downgraded from Outperform to Perform, Oppenheimer said. Thesis played out with few near term catalysts.
-----
Ingersoll-Rand cut from Focus List at Credit Suisse
IR was removed from the U.S. Focus List, according to Credit Suisse. Valuation call, based on a $41 price target.
-----
Ingersoll-Rand numbers lowered at Jefferies
Shares of IR now seen reaching $38, according to Jefferies. Estimates also cut, given reduced residential expectations. Buy rating.
-----
Keycorp estimates, target increased at Jefferies
KEY estimates were raised through 2012, Jefferies said. Operating trends are improving. Hold rating and new $7.50 price target.
-----
Laboratory Corp. numbers lowered at Credit Suisse
Shares of LH now seen reaching $91, according to Credit Suisse. Estimates also cut, given slower underlying growth trends. Neutral rating.
-----
Microsoft estimates lowered at Goldman
MSF T estimates were cut through 2014, Goldman Sachs said. Company is seeing higher operating costs. Neutral rating $29 price target.
-----
Microsoft estimates lowered at UBS
MSFT estimates lowered through 2013 on Skype and revenue mix shift, UBS said. Maintain $33 price target and Buy rating.
-----
National Penn Bancshares downgraded at Guggenheim
NPBC was downgraded from Buy to Neutral, Guggenheim said. $8 price target. Current premium valuation reflects earnings profile.
-----
Newfield Exploration numbers cut at Jefferies
Shares of NFX now seen reaching $44, according to Jefferies. Estimates also reduced, as the company is seeing limited growth opportunities. Hold rating.
-----
Noble estimates, target cut at Credit Suisse
Shares of NE now seen reaching $49, according to Credit Suisse. Estimates also reduced, as the company is seeing higher unanticipated downtime. Outperform rating.
-----
Noble Corporation estimates lowered at UBS
NE estimates lowered through 2012, UBS said. Reflects below the line items, including higher SG&A. Maintain $42 price target and Buy rating.
-----
Nucor estimates, target cut at Jefferies
Shares of NUE now seen reaching $45, according to Jefferies. Estimates also reduced, given lower expected steel demand.
-----
Pall added to Focus List at Credit Suisse
PLL was placed on the U.S. Focus List, Credit Suisse said. $61 price target. Company is cutting costs and can generate solid near-term growth.
-----
Penn National Gaming downgraded at Brean Murray
PENN was downgraded from Buy to Hold, Brean Murray said. 3Q trends remain solid, but note of caution on growth trajectory will likely depress valuation.
-----
Philip Morris numbers raised at Morgan Stanley
Shares of PM now seen reaching $78, according to Morgan Stanley. Estimates also increased, as the company is posting solid growth across the board. Overweight rating.
-----
Raymond James numbers increased at Goldman
RJF estimates were raised through 2013, Goldman Sachs said. Investment banking remains strong. Neutral rating and new $32 price target.
-----
SanDisk estimates adjusted at UBS
SNDK estimates adjusted through 2012, UBS said. Upside Q3 results with solid demand outlook heading into 2012. Buy rating.
-----
Seagate Technology upgraded at Baird
STX was upgraded from Neutral to Outperform, Robert Baird said. $17 price target. Company can take market share in the coming quarters.
-----
Southwest numbers raised at UBS
Shares of LUV now seen reaching $10, according to UBS. Estimates also increased on top line performance. Maintain Neutral rating.
-----
TCF Financial upgraded at Oppenheimer
TCB was upgraded from Perform to Outperform, Oppenheimer said. Pressure on fees now taking a backseat.
-----
TIBCO Software rated new Buy at Think
TIBX was initiated with a Buy rating, ThinkEquity said. $32 price target. Increasing adoption of mobility driving business.
-----
UHS estimates lowered at UBS
UHS estimates lowered through 2012, UBS said. Volumes remain weak despite easier comps. Maintain $55 price target and Buy rating.
-----
Union Pacific estimates raised at Citigroup
UNP estimates increased through 2012, Citigroup said. Strong quarter in a challenging market, incrementals accelerate. Maintain $106 price target and Buy rating.
-----
Union Pacific numbers raised at Credit Suisse
Shares of UNP now seen reaching $120, according to Credit Suisse. Estimates also increased, given higher realized yields. Outperform rating.
-----
Walt Disney numbers reduced at Morgan Stanley
DIS estimates were cut through 2013, Morgan Stanley said. Company lowered its guidance. Overweight rating and new $40 price target.
-----
Wynn Resorts upgraded at BMO
WYNN was upgraded from Market Perform to Outperform, BMO Capital Markets said. $167 price target. Earnings, cash flow, Cotai, all catalysts for valuation.
